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Abstract
Clostridium difﬁcile is a Gram-positive, spore-forming, human and animal pathogen that is the major cause of antibiotic-associated diarrhoea
worldwide. The past decade has seen the rapid emergence of the hypervirulent PCR ribotype (RT) 027 complex, which has been associated
with increases in the incidence and severity of disease and mortality. In this review, we describe the potential virulence factors that have
been reported in strains from the RT 027 complex. We review the emergence, population structure, dissemination and evolution of this
lineage.
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Clostridium difﬁcile: the Pathogen andDisease
C. difﬁcile is a Gram-positive spore-forming anaerobic bacillus
that is the leading cause of healthcare-associated diarrhoea in
developed countries [1–4]. Infection is caused by the ingestion
of spores from infected patients or the environment. After
antibiotic treatment, the protective gut microbiota is dis-
rupted, allowing C. difﬁcile to ﬂourish and heavily colonize the
gastrointestinal tract; this can lead to asymptomatic carriage or
infection. C. difﬁcile infection (CDI) ranges in severity from
mild and self-limiting, watery or bloody diarrhoea to severe
disease, with ileus, toxic megacolon, and pseudomembranous
colitis, that can be fatal [5]. Typical features of CDI include
watery diarrhoea, abdominal pain and cramps, lower-quadrant
tenderness, fever, leukocytosis, and hypoalbuminaemia [6].
Re-occurrences are common, with rates of up to 20% after the
ﬁrst episode of CDI and 50% after the second episode, even
after treatment [7].
Typing, Epidemiology, and Phylogenomics—
the Emergence of PCR Ribotype (RT) 027
A variety of molecular typing approaches have been developed
to investigate CDI, including ampliﬁed fragment length poly-
morphism, pulsed-ﬁeld gel electrophoresis, restriction endo-
nuclease analysis, and PCR ribotyping [8]. The preferred
method in North America is pulsed-ﬁeld gel electrophoresis,
whereas PCR ribotyping is most widely accepted in Europe [9].
In addition, multilocus sequence typing (MLST) has become
a standard technique for CDI epidemiological studies [10].
MLST studies based on diverse collections of C. difﬁcile strains
have suggested that there are ﬁve distinct lineages, which can
generally be divided according to the most important PCR
ribotype (RT): 027, 017, 023, 078, and a large group including
the other PCR RTs [11,12] (Fig. 1). The RT 078 complex is an
outlying group that is highly divergent and distantly related to
the other lineages (Fig. 1) [13]. These ﬁndings have also been
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conﬁrmed with other genome-based techniques, including a
comparative microarray-based study [14] and a whole genome
sequencing (WGS) study based on single-nucleotide polymor-
phisms (SNPs) [15].
The earliest recorded RT 027 isolate was strain CD196,
which is a non-epidemic strain isolated from a single patient
with CDI in a Parisian hospital in 1985 [16]. The next recorded
RT 027 isolate was a non-epidemic strain designated BI-1,
which was from a patient with CDI in a Minneapolis hospital in
1988 [17] (Fig. 2). In 2003–2004, Canada experienced out-
breaks involving >30 hospitals [18], with notably severe CDIs.
Between August 2004 and July 2007, >20 000 nosocomial
cases were reported to the Quebec provincial surveillance
program (R. Gilca, INSPQ, personal communication). Retro-
spective analysis showed that a similar strain had also been
isolated in several regions of the USA between 2000 and 2002.
From 2003 to 2006, two CDI outbreaks at Stoke Mandeville
Hospital, UK, caused a total of 127 deaths (Fig. 2). The annual
mortality attributable to CDI rose by 72% in the UK to 6500
cases in 2006 [19]. By 2005, RT 027 had been detected in an
outbreak in The Netherlands [20], and by 2007 it had been
isolated in 16 European countries [21,22]. The application of
genotyping methods conﬁrmed that RT 027 strains are
genetically highly uniform.
In 2008, RT 027 had reached Korea, Hong Kong, and
Singapore, and by 2009 it had been reported in Australia and
Costa Rica [23–27]. This was followed by RT 027 being
isolated in New Zealand in 2010 [28]; in Chile in 2011 [29], in
Panama in 2013 [30], and in China in 2014 [31] (Fig. 2).
RT 027 is associated with an intensifying worldwide
epidemic of nosocomial disease, with high mortality and
recurrence [19,32–34]. Since 2005, US studies have continued
to report increased CDI rates [35], and RT 027 has persisted
as the dominant clone [36]. In 2007, CDI surveillance in
Canada showed decreases in RT 027 infections and CDI
deaths in Quebec. However, there were increases in the
incidence rates of RT 027 infection in British Columbia,
Ontario, and the Atlantic provinces, accompanied by an
increase in CDI-related mortality (Annual Meeting of the
Society for Healthcare Epidemiology of America, 2009,
Abstract 350). Nevertheless, between 2008 and 2011, England
saw a 61% reduction in the number of reports of CDI, which
was reﬂected in a decline in the number of cases of CDI caused
by RT 027. The large reduction in the number of cases of CDI
caused by RT 027 in England also parallels the decrease in
CDI-related mortality (Ofﬁce for National Statistics 2012).
Alongside this decline, an increase in the prevalence of other
RTs has been observed, most notably RT 015, RT 002,
RT 078, RT 005, RT 023, and RT 106 (Clostridium difﬁcile
Ribotyping Network for England www.hpa.org.uk/webc/HPA-
webFile/HPAweb_C/1317133396963). In The Netherlands, a
3% decrease in the prevalence of RT 027 has also been
detected [37]. All of these data demonstrate that RT 027
spreads rapidly, and, although it is in decline in some
geographical areas, its transcontinental dissemination contin-
ues [38].
C. difﬁcile PCR RT 027: Virulence Factors
C. difﬁcile has traditionally proven difﬁcult to genetically
manipulate, especially RT 027 strains. Despite this, some
virulence determinants of C. difﬁcile have been studied in detail.
C. difﬁcile pathogenesis is thought to be largely based on the
production of the UDP-glycosylating enterotoxins, encoded by
tcdA and tcdB situated within a pathogenicity locus [39]. The
19.6-kb pathogenicity locus of C. difﬁcile also contains an
accessory gene, tcdE [40], along with regulatory components.
These toxins cause extensive tissue damage, and are consid-
ered to be major virulence factors in CDI [41–45]. It has been
reported that some RT 027 strains can produce more toxin
in vitro [46], and this has been attributed to deletions in the
negative regulator gene tcdC. Further studies have revealed
that the 18-bp in-frame deletion has no effect on toxin
production [47]. It has also been hypothesized that RT 027
isolates have differences in the sequence of TcdB in comparison
FIG. 1. Diagram showing the ﬁve Clostridium difﬁcile lineages and their relationship with common ribotypes (RTs). Each lineage is formed by a
speciﬁc RT complex, apart from clade/lineage 1, which is composed of a pool of different RTs.
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with RT 012 and RT 003 [48]. This variation could explain the
differences in activity found by Stabler et al. [49] in 2009,
whereby TcdB from RT 027 isolates was more potent on
cultured cells than TcdB from the historical RT 012 strain.
Variations between TcdBs from previously predominant RTs
and RT 027 strains could be a major contributory factor in the
increased virulence of the RT 027 strains [50].
In addition to TcdA and TcdB, RT 027 strains have also
been found to produce a binary toxin [51,52], encoded by two
genes, cdtA and cdtB [53], and this has been linked with
increased severity of disease [54,55].
C. difﬁcile also produces spores that are highly resistance to
adverse conditions. Spores play a key role in the transmission
of CDI, as they are resistant to a wide range of chemical and
physical stressors, and can persist in a contaminated environ-
ment for several weeks to months [56,57]. Spore germination
in the gut enables C. difﬁcile vegetative cell growth, metabo-
lism, and production of toxins A and B, which mediate
intestinal epithelium injury, inﬂammation, and colitis [58,59].
In a healthy gut, indigenous microorganisms form a protective
barrier against C. difﬁcile colonization, but this protective
function can be weakened by antibiotic therapy [60]. It has
been reported that the proportion of RT 027 spores that
germinate is much higher than the proportion of strain 630
spores that germinate [61]. In addition, RT 027 isolates
showed higher germination efﬁciencies in the presence of
0.1% (w/v) sodium taurocholate than RT 106 and RT 078
[62]. More recent studies have found that C. difﬁcile spore
germination in response to sodium taurocholate varies
signiﬁcantly, even within the RT 027 group [63]. A link
between high germination rate and CDI recurrence has
previously been reported [64].
C. difﬁcile also produces a surface layer [65], composed of
the high molecular weight surface layer protein (SLP) and the
low molecular weight SLP [66,67]. It has been demonstrated
that SlpA is conserved in RT 027 strains. Sequencing data of
different RTs (001, 012, 014, 017, 027, and 078) revealed that
SlpA is conserved among strains belonging to the same RT. In
addition, it has been reported that the antigenic role of the low
molecular weight SLP may involve immune evasion [68].
C. difﬁcile also has peritrichous ﬂagella, which are
O-linked-glycosylated. Additionally, it has been found that
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FIG. 2. Map of isolation dates and locations of Clostridium difﬁcile ribotype (RT) 027 globally.
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ﬂagellum glycosylation plays a role in ﬂagellar assembly and
motility [69].
C. difﬁcile can be resistant to many antibiotics, and, through
genomics approaches, resistance can be traced over time. The
epidemic RT 027 strains that caused outbreaks worldwide
were found to be highly resistant to ﬂuoroquinolones as
compared with the historic strain 630, owing to point muta-
tions in the DNA gyrase genes [70]. It has been suggested that,
after antibiotic treatment, recolonization of the human gut by
commensal bacteria is prevented by the production of p-cresol
by C. difﬁcile [71]. The production of p-cresol from tyrosine
appears to be speciﬁc to C. difﬁcile and lactobacillus strains [72].
To date, many virulence factors have been proposed to
contribute to the difference in virulence between historical
RTs and RT 027, such as toxin production and sporulation
[50,61]. The relative importance of these factors is still under
investigation.
C. difﬁcile PCR RT 027: Comparison with
the historical PCR RT 012 Strain 630
A recent study compared the ﬁrst fully sequenced strain 630
(RT 012), a multidrug-resistant isolate from a patient with
pseudomembranous colitis at a hospital in Zurich in 1982 [73],
with both a historical (CD196) and modern (R20291) RT 027
strain (Table 1). The study found 234 genes to be unique to
both RT 027 strains. Recent genome re-annotation in our
laboratory has revealed that RT 027 strains have a lower
number of unique genes than in the Stabler et al. [49] study
(Table 2).
In addition, it has been shown that, in strain 630, ﬂagel-
lum-associated genes are found in two loci, F1 (CD0226–
CD0240) and F3 (CD0245–CD0271), which are separated by
an inter-ﬂagellum locus F2 (CD0241–CD0244) [49]. Micro-
array analysis of this region previously showed a loss of, or
high divergence in, F1 and F2 in all RT 027 isolates tested [49].
The different genes present in the F2 region of strain 630 and
RT 027 may be important in the glycosylation of the ﬂagella.
Studies in other enteric bacteria, such as Campylobacter jejuni,
have shown that both ﬂagellin and post-translational modiﬁ-
cations of ﬂagellin are required for autoagglutination, which is
linked to virulence [74].
A large proportion of the RT 027-speciﬁc genes are
regulatory genes, with eight two-component regulators and
15 other transcriptional regulators having been found [49].
C. difﬁcile PCR RT 027: Emergence and
Microevolution
He et al. have conﬁrmed that RT 027 isolates are members of
a single lineage (Fig. 1) [15]. A Bayesian skyline plot analysis
[15] showed that RT 027 isolates underwent a population
expansion around the start of the century, which coincided
with the reporting of major hospital outbreaks caused by
RT 027 strains. The study also revealed that the C. difﬁcile
genome harbours a signiﬁcant number of mobile elements,
many of them coding for a variety of antibiotic resistance
genes, suggesting a signiﬁcant role for horizontal gene transfer
in resistance acquisition [15]. Study of the distribution of SNPs
along the conserved C. difﬁcile genome revealed an exchange
of very large chromosomal regions, within both the
deep-branching phylogeny and the RT 027 hypervirulent group
[15]. He et al. also showed that, between deeply diverging
lineages, there is evidence for strong purifying selection [15].
A more recent study showed that the core genome of
RT 027 isolates shows a relatively low level of genetic
diversity, consistent with its recent emergence, with very
few SNPs deﬁning the major branches in the phylogeny [38].
The study also showed the presence of two genetically distinct
lineages, which have independently acquired an identical
mutation (encoding a p.THr82Ile alteration) in the DNA
gyrase subunit A gene gyrA by either mutation or recombina-
tion, leading to high-level ﬂuoroquinolone resistance (FQR)
[75]. This study designated these recently emerged lineages as
FQR1 and FQR2 [38].
The FQR1 lineage contains epidemic isolates associated
with healthcare-related outbreaks in the USA [76] and isolates
associated with sporadic infections in South Korea [77] and
Switzerland between 2007 and 2010 [78]. Bayesian phylogeo-
graphical analysis indicated a 99% probability that the FQR1
lineage originated in the USA [38]. The earliest isolate in the
FQR1 lineage was obtained in Pittsburgh, Pennsylvania in 2001,
representing one of the earliest reports of an increase in CDI
frequency caused by FQR RT 027 [79,80]. FQR1 seems to
represent an epidemic lineage that originally emerged in the
north-eastern USA and that was subsequently transmitted to
South Korea and Switzerland [38]. The FQR2 lineage
represents the majority of epidemic isolates that show a
widespread geographical distribution. The most remarkable
feature in the FQR2 phylogeny is a star-like topology in the
early part of the lineage, which is generally consistent with
TABLE 1. Strains described in this review
Strains PCR ribotype Date isolated City, state/province
630 012 1982 Zurich, Switzerland
CD196 027 1985 Paris, France
R20291 027 2006 Aylesbury, UK
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rapid population expansion from a common progenitor.
Bayesian analysis suggested that the FQR2 lineage also
originated in North America [38].
The Bayesian phylogeny contains multiple highly supported
sublineages of FQR2 associated with distinct geographical
locations, suggesting rapid transcontinental dissemination from
North America to continental Europe, the UK, and Australia.
The study suggested a single introduction of FQR2 into
Australia and at least four separate introductions into conti-
nental Europe, including two trans-Atlantic transmission
events and two transmissions from the UK, giving rise to
actual isolates in Austria and Poland [81] (Fig. 2). Similarly, the
descendants of the FQR2 lineage were introduced into the UK
on at least four occasions, including three trans-Atlantic
transmissions from North America and one from continental
Europe, leading to a series of highly publicized outbreaks in UK
hospitals from 2004 to 2006 [82]. Despite multiple introduc-
tions, the majority of current UK isolates appear to be
descendants of one sublineage, which is a 2002 Birmingham
isolate. The dominant sublineage was also responsible for the
Stoke Mandeville outbreak [82].
It is believed that the acquisition of FQR in two distinct
lineages is associated with the emergence of RT 027 strains. In
addition, horizontal gene transfer is a pivotal mechanism
driving C. difﬁcile evolution [15,73]. He et al. have shown that
the separate acquisitions of FQR and a conjugative transposon
in two distinct lineages of RT 027 are the key genetic changes
linked to its rapid emergence during the early 2000s [33,76].
This study also demonstrated that the acquisition of resistance
to commonly used antibiotics is a major feature of the
continued evolution and persistence of RT 027 in healthcare
settings.
C. difﬁcile PCR RT 027 in Disguise
A group of 19 strains designated as BI (all presumed to be
RT 027) were isolated and characterized by Gerding et al. (D.
N. Gerding, personal communication). A recent study revealed
that some of the BI strains that were presumed to be RT 027
are, in fact, other RTs: BI-6 (RT 176), BI-11 (RT 198), and
BI-14 (RT 244). The banding patterns of these RTs are very
similar to that of RT 027 (plus or minus one band) (Fig. 3). A
close association between RT 027 and RT 176 has also been
found in strains isolated in the Czech Republic and Poland [81].
The reported RT 244 isolate obtained in New Zealand also
TABLE 2. Unique genes of ribotype 027 strains
R20291 CD196 Function
CDR20291_0223 CD196_0236 DTDP-4-dehydrorhamnose reductase
CDR20291_0224 CD196_0237 Glucose-1-phosphate thymidylyltransferase
CDR20291_0242 CD196_0255 Glycosyl transferase family 2
CDR20291_0243 CD196_0256 Glycosyl transferase, group 2 family
CDR20291_0310 CD196_0323 TetR (putative transcriptional regulator)
CDR20291_0439 CD196_0453 Sensor histidine kinase
CDR20291_0861 CD196_0881 Sensor protein
CDR20291_0862 CD196_0882 Predicted ABC transporter, ATPase component
CDR20291_1278 CD196_1301 Transcriptional regulator, araC family protein
CDR20291_1415 CD196_1438 Prophage lambdaBa04, site-speciﬁc recombinase, phage integrase family
CDR20291_1463 CD196_1488 N-acetylmuramoyl-L-alanine amidase (cell wall hydrolase)
CDR20291_1464 CD196_1489 Cell surface protein (putative penicillin-binding protein)
CDR20291_1847 CD196_1802 Possible transcriptional regulator
CDR20291_2278 CD196_2230 Putative peptidoglycan-binding/hydrolysing protein
CDR20291_2760 CD196_2713 Two-component system, sensor histidine kinase
CDR20291_2964 CD196_2917 Transcriptional regulator, padR-like family
CDR20291_2981 CD196_2934 Spermidine/putrescine ABC transporter ATP-binding subunit
CDR20291_2994 CD196_2947 CRISPR-associated helicase Cas3
CDR20291_2995 CD196_2948 CRISPR-associated autoregulator, devR family
CDR20291_2997 CD196_2950 CRISPR-associated protein Cas6
CDR20291_2998 CD196_2951 CRISPR-associated protein Cas5 family
CDR20291_3050 CD196_3004 ABC transporter, permease associated with salivaricin lantibiotic
CDR20291_3051 CD196_3005 Possible sensor histidine kinase
CDR20291_3123 CD196_3077 ABC transporter, ATP-binding protein
CDR20291_3124 CD196_3078 Sensor protein
CDR20291_3184 CD196_3138 Putative membrane protein
CDR20291_3185 CD196_3139 ABC transporter, ATP-binding protein
CDR20291_3186 CD196_3140 Membrane protein, putative
CDR20291_3187 CD196_3141 Accessory gene regulator
CDR20291_3188 CD196_3142 Sensor histidine kinase virS
CDR20291_3276 CD196_3230 Transposase, mutator type
CDR20291_3277 CD196_3231 Putative exported protein
CDR20291_3278 CD196_3232 Putative exported protein
CDR20291_3281 CD196_3235 Transposon Tn21 resolvase
CDR20291_3284 CD196_3238 Phage portal protein
CDR20291_3289 CD196_3243 Leucine-rich repeat protein
CDR20291_3461 CD196_3415 Chloramphenicol O-acetyltransferase
CDR20291_3469 CD196_3423 Transcriptional regulator, tetR family
CDR20291_3470 CD196_3424 ABC transporter, ATP-binding protein
CDR20291_3472 CD196_3426 Putative ABC transporter, permease protein
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shares several features with RT 027 [28]. Additionally, a study
that performed comparative genome microarray analyses
found these three RTs to be in the same clade as RT 027
[14], and an MLST study found that all three RTs cluster
together with RT 027 (Fig. 3) [13]. These results indicate that
the different typing methodologies do not correspond as well
as previously thought, and suggest that they these RTs have
co-evolved and possibly evolved from each other (Fig. 1).
Moreover, these ﬁndings highlight the importance of monitor-
ing high similarity in RT patterns between RT 027 and other
RTs, as strains belonging to these other RTs may be as
problematic as RT 027 [83]. In addition, this MLST study
showed that RT 126, RT 237, RT 280, RT 281 and RT 127
cluster together with RT 078, and that RT 212 clusters
together with RT 023 (Fig. 1). These ﬁndings suggest that
RTs in disguise are also present in other lineages, and need to
be monitored closely.
To date, the data generated with MLST, microarrays and
traditional typing methods have shown inadequate resolution
for deﬁnitive epidemiological conclusions to be drawn. There
is a pressing need to understand the micro-evolution of
C. difﬁcile. The most deﬁnitive approach is WGS, and the
advent of next-generation sequencing has greatly facilitated
the re-annotation of bacterial genomes. The application of
WGS comparisons for epidemiological and phylogenetic
studies has already been published for several bacterial
pathogens [84–86].
We do not yet fully understand the species population
structure and evolutionary history of C. difﬁcile. WGS prom-
ises to provide further insights, and it is envisaged that this
approach, alongside strong geographical, patient and epidemi-
ological data, will enable the monitoring of persistence,
transmission and evolution within hospitals by spatial-temporal
mapping of the genotypes down to the level of hospital ﬂoor
plans and patient movement within and outside hospitals.
It is anticipated that more WGS data for multiple strains
from multiple sources will allow for a detailed description of
the population structure of C. difﬁcile. Such a global reference
map will facilitate the contextualization of additional
sequenced strains, and the identiﬁcation of virulence determi-
nants.
Conclusion and Future Perspectives
C. difﬁcile is the major cause of healthcare-associated diar-
rhoea worldwide, in part because of the rapid emergence of
RT 027, which, in the last decade, has been associated with
outbreaks and increased mortality [87]. Although RT 027 is
still persistent in North America and Canada, it seems that
there has been a decrease in the frequency of CDI caused by
RT 027 in Europe, most notably in the UK (Public Health
England report, 2013). Recently, RT 027 has also been isolated
in South America [27,29] and New Zealand [28]. It is clear that
RT 027 has evolved rapidly, and its transcontinental spread is
ongoing [38]. Horizontal gene transfer and genetic recombi-
nation have played an important role in this sequence
diversiﬁcation [15].
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FIG. 3. PCR ribotyping proﬁles obtained with Clostridium difﬁcile. Ribotype (RT) 176, RT 198 and RT 244 are marked with asterisks. Lane 1: 100-bp
ladder. Lane 2: BI-1. Lane 3: BI-2. Lane 4: BI-3. Lane 5: BI-4. Lane 6: BI-5. Lane 7: BI-6 (RT 176). Lane 8: BI-6p. Lane 9: BI-6p2. Lane 10: BI-7.
Lane 11: BI-8. Lane 12: BI-9. Lane 13: BI-10. Lane 14: BI-11 (RT 198). Lane 15: BI-12. Lane 16: BI-13. Lane 17: BI-14 (RT 244). Lane 18: BI-15.
Lane 19: BI-16. Lane 20: BI-17. Lane 21: 027-01. Lane 22: 027-02. Lane 23: 027-03. Lane 24: 027-04. Lane 25: 027-05. Lane 26: 027-06. Lane 27:
027-07. Lane 28: 027-08. Lane 29: 027-09. Lane 30: 027-10. Lane 31: R20291. Lane 32: CD196.
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The RT 027 genome is highly dynamic [38]. The separate
acquisitions of FQR and a conjugative transposon in two
distinct lineages of RT 027 are the key genetic changes linked
to its rapid emergence during early 2000 [38]. Given the
current mortality associated with CDI, despite antibiotic
therapy, it may be time to take a different approach. Targeting
of speciﬁc pathways that disable C. difﬁcile could be an adjunct
to or even a replacement for antibiotic therapy.
In this review, we have presented a timeline that reﬂects the
isolation dates and locations of RT 027. A uniform typing
methodology should be implemented in all countries world-
wide, to monitor the spread of strains that are as or more
hypervirulent than RT 027. In particular, there is a need to
understand that there are RTs very similar to the hypervir-
ulent RT 027 (RT 176, RT 244, and RT 198), RT 078
(RT 126, RT 237, RT 280, RT 281, and RT 127), and
RT 023 (RT 212).
In the past, typing methods such as PCR ribotyping have
been valuable for monitoring outbreaks of C. difﬁcile. However,
with the increase in the number and variety of PCR RTs over
time, the discriminatory power of such methods has dimin-
ished, affecting their ability to characterize potential outbreak
strains as the same bacterial clone. Additionally, in a query
outbreak situation, identifying genetically very similar RTs, such
as RT 027, RT 176, RT 198, and RT 244, suggesting that an
outbreak has not occurred poses problems. It is possible that
the outbreak RT 027 strain has, during an outbreak, under-
gone changes in the size and copy number of the intergenic
spacer regions that are the diagnostic targets for PCR RT,
thereby altering the RT identity and misrepresenting an
outbreak situation. Sequencing of whole genomes offers
optimal discriminatory power, allowing laboratories to detect
transmission pathways between patients, hospital wards,
hospitals, regions, countries, and continents.
Analyses of RT 027 isolates have demonstrated that the
acquisition of resistance to commonly used antibiotics is a
major feature of its continued evolution and persistence in
healthcare environments. With the decline in RT 027 in the
UK, its increased dissemination globally, and the simulta-
neous increase in other equally virulent RTs, there is a
pressing need to understand the evolution of this lineage.
The use of next-generation technologies combined with an
understanding of the emergence and evolution of the
hypervirulent RT 027 strain will allow us to monitor the
emergence and spread of other potentially hypervirulent
strains in real time. It is envisaged that this real-time genomic
data coupled with strategies to control the spread and
treatment of CDIs will result in improved infection control
and reductions in the morbidity, mortality and costs
associated with CDI.
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